PDCD1 and sarcoma: We further explored two additional mouse models for responsiveness towards muPD1-IL2v: MCA-205 sarcoma, which is partially sensitive to PD-1 blockade, and RIP-Tag5, a spontaneous pancreatic neuroendocrine tumour model that is unresponsive to anti-PD-1 therapy.